High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis

Oncotarget

Volumn 6, Issue 13, 2015, Pages 11694-11703

  Thomas, Anish ^a   Chen, Yuanbin ^a   Steinberg, Seth M ^a   Luo, Ji ^a   Pack, Svetlana ^a   Raffeld, Mark ^a   Abdullaev, Zied ^a   Alewine, Christine ^a   Rajan, Arun ^a   Giaccone, Giuseppe ^b   Pastan, Ira ^a   Miettinen, Markku ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

EGFR; KRAS; Mesothelin; Non small cell lung cancer

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MESOTHELIN; ERBB2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; AKT1 GENE; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HER2 GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; ONCOGENE K RAS; PIK3CA GENE; PROTEIN EXPRESSION; PYROSEQUENCING; SURVIVAL TIME; THORAX CANCER; WILD TYPE; ADENOCARCINOMA; CANCER STAGING; CHEMISTRY; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHENOTYPE; PILOT STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; UNITED STATES; UPREGULATION; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE AMPLIFICATION; GENETIC PREDISPOSITION TO DISEASE; GPI-LINKED PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, ERBB-2; RISK FACTORS; UNITED STATES; UP-REGULATION; YOUNG ADULT;

EID: 84929650189     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3429     Document Type: Article

References (34)

1. Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, Goldstraw P. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007; 2:694-705.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
3. Non-small Cell Lung Cancer Collaborative Group:Chemotherapy in Non-Small-Cell Lung-Cancer - a Metaanalysis Using Updated Data on Individual Patients from 52 Randomized Clinical-Trials. Brit Med J. 1995; 311:899-909.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl J Med. 2002; 346:92-8.
5. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382:709-19.
6. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011; 22:2616-24.
7. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996; 93:136-40.
8. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003; 27:1418-28.
9. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Modern Pathol. 2003; 16:192-7.
10. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001; 7:3862-8.
11. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohisto M M. 2005; 13:243-7.
12. Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development. Mol Cancer Ther. 2012; 11:517-25.
13. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncology. 2012; 13:E301-E10.
14. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008; 44:46-53.
15. Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5:208ra147.
16. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol. 2003; 27:150-8.
17. Frierson HF Jr, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, Cathro H, Hampton GM. Largescale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003; 34:605-9.
18. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol. 2003; 27:1031-51.
19. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19:417-28.
20. Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int. 2007; 57:190-9.
21. Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CL, Abdullaev Z, Xi L, Pack S, et al. Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: a biomarker derived multi-arm, multi-histology phase II "basket" trial. J Clin Oncol. 2015; February 9.
22. Kachala SS, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou J, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res. 2014; 20:1020-8.
23. Lee S, Kang J, Cho M, Seo E, Choi H, Kim E, Kim J, Kim H, Kang GY, Kim KP, Park YH, Yu DY, Yum YN, et al. Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol. 2009; 34:161-72.
24. Hucl T, Brody JR, Gallmeier E, Iacobuzio-Donahue CA, Farrance IK, Kern SE. High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor-dependent MCAT motif. Cancer Res. 2007; 67:9055-65.
25. Lee I, Gould VE, Radosevich JA, Thor A, Ma YX, Schlom J, Rosen ST. Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms. Virchows Arch B Cell Pathol Incl Mol Pathol. 1987; 53:146-52.
26. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008; 99:2020-8.
27. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012; 142:730-733.
28. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, Yeo CJ, Hruban RH. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol. 2003; 16:902-12.
29. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I. Mesothelin expression in human lung cancer. Clin Cancer Res. 2007; 13:1571-5.
30. Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012; 18:858-68.
31. Schatz CA, Golfier S, Scheider C, Kopitz C, Berhörster K, Henderson D, Schmitz A, Krahn T, Kreft B, Ziegelbauer K. Efficacy and candidate biomarker evaluation for the antimesothelin antibody drug conjugate (ADC) BAY 94-9343, mesothelin-ADC in mesothelin-positive preclinical xenograft models (abstract). Cancer Res. 2012; 72:2726.
32. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010; 16:6132-8.
33. Pack SD, Zhuang Z. Fluorescence in situ hybridization :application in cancer research and clinical diagnostics. Methods Mol Med. 2001; 50:35-50.
34. Mehta CR, Patel NR. A Network Algorithm for Performing Fisher Exact Test in R X C Contingency-Tables. J Am Stat Assoc. 1983; 78:427-34.